Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Expedition raises $115m Series B to advance COPD drug EXPD-101, with support from General Atlantic and other investors, strengthening their regulatory and operational capabilities.
PRIVATEAug 05, 2026•4 days ago
Amount Raised
$115 Million
Round Type
Series B
BiotechnologyHealth CareTherapeutics
Investors
General Atlantic
Description
Expedition has successfully raised $115 million in Series B financing to progress its EXPD-101 drug for chronic obstructive pulmonary disease (COPD). The funds will be utilized to enhance clinical, regulatory, and operational capabilities while expanding their pipeline. The company aims to generate high-quality clinical data to improve treatment options for COPD patients. This round attracted a strong syndicate of investors who align with Expedition's long-term vision.
Related People
Suggested for you
2 contactsVerified contactsRob, Co-Founder hidden
Funding Insights
Based on industry dataTimeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech